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FGF-23 - Fibroblast growth factor-23  
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ABSTRACT  
 
BACKGROUND:  
Klotho is an ‘anti-ageing’ hormone and transmembrane protein; Klotho deficient mice develop a 
similar ageing phenotype to smokers including emphysema and muscle wasting. The objective of this 
study was to evaluate skeletal muscle and circulating Klotho protein in smokers and COPD patients 
and to relate Klotho levels to relevant skeletal muscle parameters. We sought to validate our 
findings by undertaking complimentary murine studies. 
 
METHODS:  
Fat free mass, quadriceps strength and spirometry were measured in 87 participants (61 COPD, 13 
‘healthy smokers’ and 13 never smoking controls) in whom serum and quadriceps Klotho protein 
levels were also measured. Immunohistochemistry was performed to demonstrate the location of 
Klotho protein in human skeletal muscle and in mouse skeletal muscle in which regeneration was 
occurring following injury induced by electroporation. In a separate study, gastrocnemius Klotho 
protein was measured in mice exposed to 77 weeks of smoke or sham air.  
 
RESULTS:  
Quadriceps Klotho levels were lower in those currently smoking (p=0.01), irrespective of spirometry, 
but were not lower in patients with COPD. A regression analysis identified current smoking status as 
the only independent variable associated with human quadriceps Klotho levels, an observation 
supported by the finding that smoke exposed mice had lower gastrocnemius Klotho levels than sham 
exposed mice (p=0.005).  Quadriceps Klotho levels related to local oxidative stress but were 
paradoxically higher in patients with established muscle wasting or weakness; the unexpected 
relationship with low fat free mass was the only independent association. Within locomotor muscle, 
Klotho localized to the plasma membrane and to centralized nuclei in humans and in mice with 
induced muscle damage. Serum Klotho had an independent association with quadriceps strength but 
did not relate to quadriceps Klotho levels or to spirometry.   
 
CONCLUSIONS:  
Klotho is expressed in skeletal muscle and levels are reduced by smoking. Despite this, quadriceps 
Klotho protein expression in those with established disease appears complex as levels were 
paradoxically elevated in COPD patients with established muscle wasting. Whilst serum Klotho levels 
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were not reduced in smokers or COPD patients and were not associated with quadriceps Klotho 
protein, they did relate to quadriceps strength. 
  
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
INTRODUCTION 
 
Klotho is an ageing suppressor gene, which encodes a single pass transmembrane protein, known to 
be expressed in various tissues including the kidney, parathyroid gland, choroid plexus and skeletal 
muscle. Circulating Klotho arises either directly from transcription of a truncated, secretable form of 
the protein or by cleavage of the extracellular domain of the full length transmembrane protein (1, 
2). Klotho deficient mice develop an ageing phenotype characterised by a shortened life span and 
the clinical features of Chronic Obstructive Pulmonary disease (COPD) including emphysema and 
sarcopenia (3, 4). Consequently, reduced Klotho may contribute to some of the systemic aspects of 
COPD, including skeletal muscle function deficits that significantly impact morbidity and mortality (5, 
6). As skeletal muscle retains plasticity in response to anabolic stimuli, treating this aspect of the 
disease is an attractive therapeutic option (7) making Klotho a candidate target in COPD. 
 
Further evidence for a putative role of Klotho in the muscle dysfunction of COPD comes from a range 
of studies in man.  Serial data from a single cohort of older adults in a general population, has linked 
low circulating Klotho levels with reduced grip strength (1), disability (8) and increased mortality (9).  
Data on Klotho in COPD had previously been restricted to two studies which indirectly investigated 
the effects of genetic polymorphisms which might influence Klotho expression (10, 11).  Very 
recently, systemic Klotho levels and airway Klotho expression have been demonstrated to be lower 
in patients with COPD but the relevance to skeletal muscle function was not assessed (12, 13).  
Furthermore, current smoking status seems to attenuate circulating (14, 15) and airway (12, 13) 
Klotho levels.  Since in developed countries smoking is the usual aetiological factor in COPD, a 
pathophysiological role for Klotho signalling in the development of skeletal muscle function deficits 
is possible; however there are currently no data available on human Klotho protein within skeletal 
muscle.  
 
To assess a role for Klotho in the aetiology of skeletal muscle dysfunction in COPD, we addressed the 
following specific hypotheses. First, that Klotho protein can be detected in human skeletal muscle 
and that levels are reduced in the quadriceps of COPD patients and smokers.  Second, that 
quadriceps Klotho levels are most reduced in patients with skeletal muscle function deficits and that 
local levels relate to local oxidative stress.  Third, that serum and quadriceps Klotho levels would  
relate to phenotypic aspects of muscle function in COPD.  To better understand the effects of Klotho 
within skeletal muscle we also evaluated Klotho expression in a smoking mouse model and assessed 
its expression in the context of muscle damage induced by electroporation.  Because Klotho is a co-
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receptor for Fibroblast growth factor-23 (FGF-23), where possible we also sought to evaluate FGF-23 
levels.  
 
METHODS 
 
Human studies 
 
Studies were conducted in accordance with the amended Declaration of Helsinki, ethics committee 
approval was obtained (West London REC 3: 10/H0706/9) and participants gave informed written 
consent. COPD was diagnosed according to GOLD guidelines (16). Exclusion criteria included being 
younger than 40 or older than 90 years of age, exacerbation or use of oral corticosteroids within the 
preceding 4 weeks, significant neurological or musculoskeletal limitation, inflammatory disease, 
respiratory disease (other than COPD) or cardiac, renal or hepatic disease.  Never smokers (n=13), 
smokers with normal spirometry termed ‘healthy smokers’ (n=13) and COPD patients (including 
current smokers and former smokers) were recruited (n=61).  Demographic data were recorded and 
spirometry (17), Body mass index (BMI), fat free mass (FFM) by bioimpedence (18) and dominant leg 
isometric quadriceps maximum voluntary contraction (QMVC) (19) were measured. Fat free mass 
index (FFMI) was calculated from the bioimpedance data (18). Patients were identified as having 
skeletal muscle wasting or quadriceps weakness by using recognised cut-offs (FFMI <15kg/m
2
 in 
females or 16kg/m
2
 in males and QMVC/BMI <1.20) (5, 6).  
 
Percutaneous vastus lateralis biopsies were performed as previously described (20). 
Immunohistochemistry was performed to assess the localization of Klotho in muscle and to 
determine fibre proportions (21). Klotho (IBL, Japan), FGF-23 (EMD Millipore, MA, USA) and protein 
carbonyl levels (Biocell, Papatoetoe, NZ) were determined by enzyme linked immunosorbent assay 
(ELISA) from muscle protein extracts. Serum Klotho and FGF-23 levels were also determined by 
ELISA. 
 
Mouse studies 
 
The localization of Klotho was assessed in mouse muscle regenerating after injury caused by 
electroporation of a control DNA plasmid in experiments approved by the Royal Veterinary College 
Ethical Review Process (ERP-A-2010-WS01) and licensed by the UK Secretary of State for the Home 
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Office as Project Licence PPL 70/6797. The methodology for this is described elsewhere and is 
detailed further in the online supplement (22). 
 
In a second and independent mouse study Klotho levels were determined from the gastrocnemius of 
female C57BL/6 mice exposed to either sham or smoked air inhalation over a 77 week period as 
described elsewhere (23).  
 
Statistical analyses 
 
Statistical analyses and graphical presentations were performed using GraphPad Prism 5 (GraphPad 
Software, San Diego, USA) or SPSS version 18 (IBM, USA). Significance was set at a 2-tailed p-value of 
≤0.05. Parametric data are presented as mean (SD) and non-parametric data are presented as 
median (25
th
, 75
th
 centiles).  
 
A complete report of the Methods and a summary of the relevant studies undertaken is included in 
the online supplement, as is a more detailed description of the statistical analyses. 
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RESULTS 
 
The characteristics of the 87 participants with serum and quadriceps Klotho measurements are 
shown in Table 1.  The groups were well matched except that ‘healthy smokers’ were significantly 
younger than both never smokers and COPD patients; this is relevant since in population studies 
circulating Klotho falls with increasing age (8). The COPD patients had evidence of quadriceps 
weakness. 
 
Human quadriceps Klotho expression 
 
Quadriceps Klotho protein levels were not different between never smokers, ‘healthy smokers’ and 
COPD patients (Figure 1A). When combined irrespective of spirometric status, despite being a mean 
of 6 years younger, current smokers had lower quadriceps Klotho levels than former smokers 
(p=0.01; Figure 1B and e-Table 1). When confining the analysis to patients with COPD, current 
smokers still had reduced quadriceps Klotho levels (p=0.02; Figure 1C and e-Table 2).  
 
Protein carbonyl determinations were available in 68 participants: 7 never smokers, 13 ‘healthy 
smokers’ and 47 COPD patients, levels did not differ between these groups; ANOVA p=0.36, nor 
were they different in current smokers whether compared with either all non-current smokers 
(p=0.88) or never smokers (p=0.86). Across the cohort as a whole, protein carbonyls did not 
correlate with FFMI, QMVC, or QMVC/BMI, however, they did relate weakly to quadriceps Klotho 
protein levels (r=0.32, p=0.009), this relationship was also observed when limiting the analysis to 
COPD patients (r=0.34, p=0.02; e-Figure 1). 
 
To identify the most relevant factors associated with quadriceps Klotho levels, regression analyses 
were performed. In the cohort as a whole (Table 2), only current smoking was observed to relate to 
quadriceps Klotho levels. When limiting the analysis to patients with COPD (e-Table 3) current 
smoking did not relate to quadriceps Klotho levels, but local protein carbonyls and the presence of a 
reduced FFMI did; the association with reduced FFMI was the only independent relationship 
observed. 
 
Unexpectedly, we observed increased quadriceps Klotho levels in patients with a reduced FFMI 
(p=0.02; Figure 2A) and Klotho tended to be increased in patients with reduced QMVC/BMI (p=0.06; 
Figure 2B). Patients with both reduced FFMI and QMVC/BMI had higher quadriceps Klotho levels as 
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compared to those with preserved FFMI and QMVC/BMI (Kruskal Wallis p=0.008; Figure 2C). There 
was no difference between the proportions of current smokers and former smokers between each 
of these groups; p=0.40. Although a similar trend was observed between protein carbonylation and 
Klotho levels in patients with a reduced FFMI and reduced QMVC/BMI (e-Figure 2; e-Tables 4 and 5), 
only COPD patients with reduced QMVC/BMI and FFMI (n=6) were observed to have increased 
protein carbonylation and increased Klotho protein levels. 
 
FGF-23 levels were very low and all but one determination was lower than the lowest standard 
concentration; subsequently FGF-23 levels were not evaluated any further.   
 
Localisation of skeletal muscle Klotho 
 
The presence of Klotho protein within human muscle was confirmed and Klotho was demonstrated 
to be localized to the muscle fibre membrane and to be associated with centralised nuclei (Figure 
3A). Immunohistochemistry was available to provide fibre type data from vastus lateralis biopsies in 
65 participants (9 never smokers, 13 ‘healthy smokers’ and 43 COPD patients).  There was no 
relationship between quadriceps Klotho levels and fibre type proportions either in the cohort as a 
whole or in COPD patients considered alone (r=0.04, p=0.95 and r=-0.20, p=0.21 respectively).  
 
Animal Studies 
 
Immunohistochemistry on the gastrocnemius muscles of electroporated mice confirmed significant 
Klotho expression to be present in damaged skeletal muscle tissue, but not healthy tissue, 
furthermore, Klotho co-localized to both the plasma membrane and to centralized nuclei (Figure 3B).  
 
In mice exposed to smoke (n=19), there was a reduction in gastrocnemius Klotho levels as compared 
to those sham exposed (n=9); p=0.005, Figure 4.  
 
Klotho in the circulation 
 
There was no correlation between serum and quadriceps Klotho levels (r=0.17, p=0.13). Circulating 
Klotho levels and demographic data are shown in e-Figure 3 and Table 1.  Serum Klotho levels did 
not differ between never smokers, ‘healthy smokers’ or COPD patients (e-Figure 3).  
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Klotho levels correlated with quadriceps strength, measured as QMVC/BMI, in the cohort as a whole 
(r=0.37, p<0.0001; e-Figure 4) and also when limiting the analysis to patients with COPD (r=0.29, 
p=0.02). To establish whether serum Klotho levels related to QMVC/BMI after accounting for other 
relevant variables, multiple regression analysis was performed. Serum Klotho maintained an 
independent relationship with QMVC/BMI (e-Table 6).  
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DISCUSSION 
 
The main finding of this study is that quadriceps Klotho protein expression is lower in current 
smokers, whether evaluated in patients with COPD alone and or when also including individuals with 
normal spirometry.  A causal role for cigarette smoking was confirmed by the use of a smoking 
mouse model.  Within skeletal muscle, Klotho is located on the muscle fibre membrane and 
associated with centralised nuclei, suggesting Klotho may have a role in regeneration, consistent 
with the known sarcopenia demonstrated by Klotho deficient mice.  Unexpectedly, the weakest 
COPD patients displayed the highest Klotho levels suggesting that Klotho mediated pathways are 
active, albeit that activity did not prevent muscle loss, and we demonstrated using electroporated 
mice that upregulation of Klotho can occur in the setting of muscle damage. 
  
Critique of the method 
 
Cross-sectional human studies are always vulnerable to the suggestion that observations may be 
epiphenomena rather than representing causality.  Ultimately this dilemma can only be resolved by 
the use of an interventional study in man and we are not aware of any currently available Klotho 
mimetics with which this experiment could be tried.  Nevertheless, we attempted to mitigate this 
risk both by studying a large number of human subjects and by undertaking supportive animal 
studies. 
 
Klotho has, to our knowledge, never been specifically measured in human muscle before, therefore 
our findings whilst novel, also require confirmation, especially since in the case of FGF-23, for which 
it is a co-receptor, we found that levels were too low to be meaningfully interpreted. The finding of 
increased quadriceps Klotho levels in patients with established skeletal muscle wasting or weakness 
and of a positive, if weak, relationship with local oxidative stress were unexpected. It was 
hypothesised that elevated Klotho levels may be a physiological response; such a protective role was 
supported by a physical association with centralised nuclei, the hallmark of regenerating fibres. 
These findings were corroborated in regenerating mouse muscle where there was demonstrated to 
be significant Klotho expression and, as in humans, Klotho co-localized to centralised nuclei in 
regenerating fibres.  
 
Significance of the findings 
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Historically the cachexia of COPD tended to be regarded as an end-stage event; however, several 
lines of data now support the concept of locomotor muscle atrophy and weakness as an early 
feature of the disease, supporting a connection with smoking which precedes clinical COPD.  Firstly, 
lower limb muscle weakness is more prevalent than loss of whole body fat free mass (24, 25) in 
COPD.  Secondly, it has been clearly demonstrated that rectus femoris cross sectional area and 
quadriceps maximal voluntary contraction force are reduced in patients with mild disease, in whom 
there is only minimal pulmonary impairment to exercise (26).  Thirdly, muscle biopsy studies have 
shown changes which we would now recognise as typical of COPD, such as type II fibre shift or loss 
of oxidative enzymes, in smokers compared with non-smokers (27) and of oxidative stress in 
smokers with normal spirometry (28).  Similarly, Gagnon et al (29) found evidence of impaired 
angiogenic signalling in the quadriceps of patients with minimal airflow obstruction, however, as 
controls had a very similar tobacco history to the patients it was impossible to evaluate the effect of 
smoking.  Fourthly, muscle weakness was found to be common amongst breathless patients 
assessed in community practice even when spirometry was within the normal range (30). 
 
If muscle weakness is accepted as an early feature of COPD, then the question arises as to the 
mechanism which causes it.  Rightly, much attention has focused on physical activity which is indeed 
reduced in patients with mild disease (29, 31).  Cigarette smoking is another candidate mechanism; 
Van den Borst and co-workers were able to show that body composition was very similar between 
patients with obstructive lung disease and smokers without obstructive lung disease and that both 
groups differed from never smokers, again supporting a prior triggering role for smoking (32).  
Similarly, Van Remoortel and co-workers (33) found co-morbidities including muscle weakness to be 
as prevalent in smokers with normal lung function as in patients with previously undiagnosed COPD, 
and in both cases to be more prevalent than in never smokers. More recently, it has been 
demonstrated that Klotho is reduced in the airway epithelial cells and alveolar macrophages of both 
smokers and COPD patients (12, 13) and that cigarette smoke reduces Klotho expression which 
subsequently confers augmented inflammation (13). Putative roles for smoking and physical activity 
in the aetiology of skeletal muscle weakness are not mutually exclusive.  It would be insightful to 
know in the context of the present data whether Klotho genotype influences the response to 
exercise training or, alternatively, whether smoking status influences this response.  Data on the 
latter are to our knowledge confined to one small scale study reported in abstract form (34). 
 
The role of Klotho within skeletal muscle is not demonstrated by our findings, however based on 
data in the literature the most plausible proposal is that Klotho acts through the attenuation of 
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oxidative stress, which would be consistent with our finding of a relationship between quadriceps 
Klotho levels and protein carbonylation. Yamamoto et al showed that recombinant Klotho protected 
cells from oxidative stress in vitro and that manganese superoxide dismutase was increased in the 
muscle of Klotho over-expressing mice - consistent with a protective effect in vivo. However, they 
did not measure Klotho levels in muscle, indeed the mouse model used over-expressed Klotho in the 
brain and testis, suggesting that effects on muscle gene expression were mediated by circulating 
Klotho (35). Oxidative stress is increased in the quadriceps of smokers and COPD patients, in whom it 
relates to skeletal muscle dysfunction (36). Although we only demonstrated increased oxidative 
stress in weak patients, smokers with normal spirometry exhibit evidence of nitrosative stress (28). 
Recent work demonstrates an association between Klotho expression and smoking and that this 
interaction affects oxidative stress in the lungs. Li et al demonstrated that knockdown of 
endogenous Klotho augments the expression of inflammatory mediators, including MMP-9, IL-6 and 
TNF-alpha by alveolar macrophages and that exogenous Klotho inhibited the expression of cigarette 
smoke induced inflammation (13).  This group extended their work to demonstrate Klotho depletion 
increases sensitivity to cigarette smoke-induced inflammation and oxidative stress-induced cell 
damage in epithelial cells where these effects involved the nuclear factor κB, mitogen-activated 
protein kinase and nuclear factor erythroid 2-related factor 2 pathways (12).  
 
Modulation of Klotho or the effects of reduced Klotho offers a potential therapeutic opportunity in 
COPD; Nagai et al were able to show that an anti-oxidant, α-tocopherol, attenuated the 
manifestations of oxidative stress in the brain of Klotho knockout mice (37). While α-tocopherol was 
shown to be safe in over 29,000 smokers, measures which might have detected a beneficial effect on 
skeletal muscle were not obtained (38). Nonetheless, consistent with our own findings, a large 
prospective study has recently observed plasma Klotho levels to be higher in those with greater 
lower limb strength, furthermore baseline Klotho levels were predictive of loss of strength over time 
(39). In the present study, systemic and quadriceps Klotho levels were simultaneously measured for 
the first time and we observed that local and systemic levels were unrelated. This may be a 
consequence of Klotho being expressed in multiple tissues and in this regard circulating Klotho may 
reflect overall Klotho activity  whilst local quadriceps Klotho protein levels may be influenced by a 
combination of local factors (for example contractile history) in addition to circulating levels. Despite 
this complex interplay, given that myotube diameter is increased by Klotho-FGF23 fusion 
polypeptide treatment, Klotho augmentation warrants further study, especially in smokers (36).  
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In conclusion, smokers irrespective of spirometric status, were found to have reduced quadriceps 
expression of Klotho, an effect replicated in a smoking mouse model suggesting a role for Klotho as a 
mediator of quadriceps weakness in COPD patients.  However, in electroporated mouse experiments 
we show a role for Klotho in regeneration of damaged muscle.  Since Klotho levels were also higher 
in the quadriceps of patients with muscle weakness we suspect that Klotho mediated regeneration 
may be attempting to restore skeletal muscle function, albeit with incomplete success. 
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TABLES 
 
Table 1. Demographics and characteristic data of never smokers, ‘healthy smokers’ and COPD 
patients, groups differences are assessed by Chi-square and ANOVA or Kruskal-Wallis. *, ** or *** 
denote significant difference at p <0.05, <0.01 and <0.001 respectively as compared to never 
smokers and 
ǂ
, 
ǂǂ
 or 
ǂǂǂ
 denote significant difference at p <0.05, <0.01 and <0.001 respectively as 
compared to ‘healthy smokers’. Data expressed as mean ± SD or median (IQR). 
 
 Never smokers 
(n=13) 
‘Healthy smokers’ 
(n=13) 
COPD 
(n=61) 
P-value 
Age (years) 65 (8) 51 (7) *** 64 (10) <0.0001 
% Male  77 38 62 0.12 
Pack years 0 (0) 38 (28) *** 45 (24) *** <0.0001 
%  Current smokers 0 100  46 <0.0001 
FEV1 (%pred) 108 (12) 99 (10) 51 (24) *** <0.0001 
BMI (kg/m
2
) 26.4 (4) 28.2 (7) 26.5 (7) 0.66 
FFMI (kg/m
2
) 19.1 (4) 18.3 (3) 17.8 (3) 0.39 
QMVC (kg) 37.9 (9) 40.1 (12) 30.5 (10) 
ǂ
 0.003 
QMVC/BMI  1.45 (0.3) 1.44 (0.4) 1.20 (0.4) 0.05 
 
Abbreviations: BMI - Body mass index,  FEV1%pred - Forced expiratory volume in 1 second, 
expressed as a percentage of predicted value, FFMI - Fat-free mass index, QMVC - Quadriceps 
maximal voluntary contraction. 
Table 2. Univariate regression analysis to determine the parameters associated with quadriceps 
Klotho levels (n=87).  
 
 Variable Mean (SD)/ 
% 
Univariate regression 
 
 
Demographics 
& spirometry 
Coefficient  
(95% CI) 
Standardised 
coefficent 
p 
Age (years) 62 (10) 0.14 (-0.07, 0.36) 0.15 0.17 
Male gender  66 1.8 (-2.7, 6.3) 0.09 0.43 
Current smoker  48 -5.1 (-9.4, -0.9) -0.25 0.02 
COPD  70 0.03 (-4.8, 4.8) 0.01 0.99 
FEV1 (%pred) 67 (32) 0.01 (-0.06, 0.08) 0.03 0.80 
 
 
Muscle 
parameters 
BMI (kg/m
2
) 26.7 (6) 
 
-0.17 (-0.51, 0.17) -0.11 0.32 
FFMI (kg/m
2
) 18.1 (3.1) -0.22 (-0.92, 0.48) -0.07 0.53 
QMVC (kg) 33.1 (11) -0.14 (-0.34, 0.06) -0.15 0.16 
QMVC/BMI 1.28 (0.42) -2.2 (-7.4, 3.0) -0.09 0.41 
 
Abbreviations: BMI - Body mass index,  FEV1%pred - Forced expiratory volume in 1 second, 
expressed as a percentage of predicted value, FFMI - Fat-free mass index, QMVC - Quadriceps 
maximal voluntary contraction. 
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FIGURE LEGENDS 
 
Figure 1 - Klotho levels in vastus lateralis muscle homogenates from A) Never smokers (n=13), 
‘healthy smokers’ (n=13) and COPD patients (n=61), B) non-current smokers (never smokers and ex-
smokers; n=46) and current smokers (n=41) irrespective of COPD status, and C) COPD former 
smokers (n=33) and COPD current smokers (n=28). Bars demonstrate the mean and standard 
deviation. 
 
 
 
Figure 2 - Klotho levels in vastus lateralis muscle homogenates from COPD patients with A) 
preserved fat free mass (FFMI ≥15 in females or 16kg/m
2
 in males; n= 45) as compared to those with 
reduced fat free mass (n= 16), B) preserved quadriceps strength (QMVC/BMI ≥1.20; n=30) as 
compared to those with loss of quadriceps strength (n=31), and C) preserved fat free mass and 
quadriceps strength (n=21) as compared to those with reduced quadriceps strength or fat free mass 
(n=32) and those with reduced quadriceps strength and fat free mass (n=8). 
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Figure 3 - Immunohistochemistry of A) human vastus lateralis muscle with blue DAPI nuclear 
staining only (left panel) and with Klotho staining green (centre panel) and a merged image with 
both Klotho and DAPI staining demonstrating Klotho to co-localize to an intracellular nucleus (right 
panel), and B) mouse gastrocnemius muscle with blue DAPI staining and Klotho staining in red, from 
a healthy mouse (left panel), at the site of injury following electroporation (centre panel) and distant 
to the site of injury following electroporation (right panel). Different colours are present for Klotho 
staining in human and mouse muscle due to the availability of secondary antibodies. The arrow 
highlights the presence of an intracellular nucleus in A) and in B) an example of one of numerous 
intracellular nuclei at the site of injured mouse muscle (centre), but only one distant to the site of 
injury (right). 
 
Figure 4 - Klotho levels in gastrocnemius muscle homogenates obtained from mice exposed to sham 
or smoked air over a 77 week period. Bars demonstrate the mean and standard deviation. 
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HIGHLIGHTS 
 
• Klotho is expressed in skeletal muscle where levels are reduced by smoking 
• In COPD, quadriceps Klotho levels are paradoxically raised in patients with wasting 
• Klotho may have a role in the process of skeletal muscle regeneration  
• Systemic Klotho levels are associated with quadriceps strength 
• Smoking may mediate skeletal muscle dysfunction by influencing  Klotho expression 
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